As a prognostic marker, several studies have found that IDH1/2 mutations are linked to prolonged patient survival and therapeutic response amongst patients with gliomas and GBM (Cairncross et al., 2014; Chen et al., 2016; Parsons et al., 2008; Yan et al., 2009). This evidence concerns the gene IDH1 and central nervous system cancer.